throughout and that the above-quota tariff rate decrease by five percentage points during each year of the remedy period. Chairman Schmidtlein and Commissioner Williamson additionally recommend an in-quota tariff rate of 20 percent *ad valorem,* which would decrease to 18 percent in the second year of the remedy period and 15 percent in the third year of the period, in addition to the current rate of duty. Vice Chairman Johanson and Commissioner Broadbent do not recommend an additional in-quota tariff rate for large residential washers.

The Commissioners also unanimously recommend that the President impose a separate TRQ on imports of covered parts of large residential washers for a duration of three years. For U.S. imports of covered parts that exceed 50,000 units, they recommend a tariff rate of 50 percent *ad valorem,* in addition to the current rate of duty. They recommend that the in-quota volume increase by 20,000 units in each year of the remedy period, and that the above-quota tariff rate decrease by five percentage points each year. They do not recommend an in-quota tariff rate for covered parts.

SUMMARY OF COMMISSIONERS' RECOMMENDED ACTIONS LARGE RESIDENTIAL WASHERS

	Year 1	Year 2	Year 3
Large Residential Washers: TRQ			
In-Quota Volume Level	1.2 million units	1.2 million units	1.2 million units.
Above-Quota Tariff Rate	50%	45%	40%.
In-Quota Tariff Rate (*Schmidtlein & Williamson*)	20%	18%	15%.
In-Quota Tariff Rate (*Johanson & Broadbent*)	0%	0%	0%.
Covered Parts: TRQ			
In-Quota Volume Level	50,000 units	70,000 units	90,000 units.
Above-Quota Tariff Rate	50%	45%	40%.
In-Quota Tariff Rate	0%	0%	0%.

Having made negative findings with respect to imports from Canada and Mexico under section 311(a) of the North American Free Trade Agreement Implementation Act, the Commissioners recommend that imports from Canada and Mexico be excluded from the above TRQs and increased rates of duty. The Commissioners also recommend that the above TRQs and increased rates of duty not apply to imports from Australia, Colombia, Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Israel, Jordan, Korea, Nicaragua, Panama, Peru, and Singapore, or to imports from the beneficiary countries under the Caribbean Basin Economic Recovery Act.

Availability of the public version of the report. The public version of the Commission's report containing the Commission's injury determination, its remedy recommendations, an explanation of the basis for its injury determination and remedy recommendations, and a summary of the information obtained in the investigation is contained in *Large Residential Washers,* Inv. No. TA–201–076, USITC Publication 4745, December 2017.

By order of the Commission.

Issued: December 4, 2017.

Katherine M. Hiner,

Supervisory Attorney.

[FR Doc. 2017–26451 Filed 12–7–17; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceutical, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before February 6, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (''Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on September 19, 2017, Janssen Pharmaceutical, Inc., Buildings 1–5 & 7–14, 1440 Olympic Drive, Athens, Georgia 30601 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Methylphenidate	1724	II
Oxycodone	9143	II
Hydromorphone	9150	II
Hydrocodone	9193	II
Oripavine	9330	II
Thebaine	9333	II
Oxymorphone	9652	II
Tapentadol	9780	II
Fentanyl	9801	II

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers.

Dated: November 17, 2017.

Demetra Ashley,

Acting Assistant Administrator.

[FR Doc. 2017–26507 Filed 12–7–17; 8:45 am]

BILLING CODE 4410–09–P